Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis argues India’s interpretation of the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights agreement is too strict and focuses too much on efficacy to the exclusion of bioavailability.

You may also be interested in...



Indian Court Hands Novartis Setback In Gleevec Patent Case

Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)

Indian Court Hands Novartis Setback In Gleevec Patent Case

Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.

Indian Court Hands Novartis Setback In Gleevec Patent Case

Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel